We found glioma patients with high-expression of LINC00675 had shorter disease-free survival (P<0.001, Figure 2A) and overall survival time (P<0.001, Figure 2B) than those with low-expression of LINC00675. This evidence concerns the gene TMEM238L and central nervous system cancer.